Boston Scientific Corp. v. Edwards Lifesciences Corp.

On December 11, 2018, the jury issued its verdict in the U.S. District Court for the District of Delaware’s case of Boston Scientific Corp. v. Edwards Lifesciences Corp. The jury determined that (i) the asserted claims of U.S. Patent No. 7,510,575 (“the ‘575 Patent”) were not infringed and not invalid; (ii) the asserted claims of U.S. Patent No. 8,992,608 (“the ‘608 Patent”) were infringed and not invalid; (iii) the asserted claims of U.S. Patent No. 9,168,133 (“the ‘133 Patent”) were not infringed and not invalid and (iv) the asserted claims of U.S. Patent No. 9,339,383 (“the ‘383 Patent”) were not infringed and not invalid. The jury awarded $35,417,685 in damages to Boston Scientific Corp. (“the Plaintiff”) for the infringement of the ‘608 Patent.

In the underlying case, the Plaintiff brought suit for patent infringement of the ‘608 Patent against Edwards Lifesciences Corp. (“the Defendant”). The ‘608 Patent, which is owned by the Plaintiff, is drawn to prosthetic heart valves. Defendant also accused Plaintiff of infringing its ‘575, ‘133, and ‘383 Patents.  These patents are also directed to prosthetic heart valves. The case remains pending and is captioned 1:16-cv-00275 (D. Del.).

By:  April Breyer Menon

View Attachment (PDF)